{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:59:13Z","timestamp":1778767153787,"version":"3.51.4"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T00:00:00Z","timestamp":1542672000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"DOI":"10.3389\/fimmu.2018.02691","type":"journal-article","created":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T04:45:39Z","timestamp":1542689139000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":39,"title":["Delivery of IL-35 by Lactococcus lactis Ameliorates Collagen-Induced Arthritis in Mice"],"prefix":"10.3389","volume":"9","author":[{"given":"Massimo","family":"Maddaloni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Kochetkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2018,11,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s00296-017-3726-1","article-title":"Prevalence of rheumatoid arthritis in the United States adult population in healthcare claims databases, 2004-2014","volume":"37","author":"Hunter","year":"2017","journal-title":"Rheumatol Int."},{"key":"B2","first-page":"1316","article-title":"The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study","volume-title":"Ann Rheum Dis.","author":"Cross","year":"2014"},{"key":"B3","doi-asserted-by":"publisher","first-page":"246","DOI":"10.15585\/mmwr.mm6609e1","article-title":"Prevalence of doctor diagnosed arthritis and arthritis attributable activity limitation\u2014United States, 2013\u20132015","volume":"66","author":"Barbour","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"B4","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.berh.2010.10.001","article-title":"Rheumatoid arthritis","volume":"24","author":"Carmona","year":"2010","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"B5","first-page":"1094","article-title":"Rheumatoid arthritis","volume-title":"Lancet","author":"Scott","year":"2012"},{"key":"B6","first-page":"1484","article-title":"Synovial inflammation, immune cells and their cytokines in osteoarthritis: a review","volume-title":"Osteoarthritis Cartilage","author":"de","year":"2012"},{"key":"B7","doi-asserted-by":"publisher","first-page":"263625","DOI":"10.1155\/2014\/263625","article-title":"Cytokine-mediated bone destruction in rheumatoid arthritis","volume":"2014","author":"Jung","year":"2014","journal-title":"J Immunol Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1136\/ard.2007.076430","article-title":"Utility of animal models for identification of potential therapeutics for rheumatoid arthritis","volume":"67","author":"Hegen","year":"2008","journal-title":"Ann Rheum Dis."},{"key":"B9","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1002\/art.1780310816","article-title":"Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum","volume":"31","author":"Saxne","year":"1988","journal-title":"Arithitis Rheum."},{"key":"B10","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.4049\/jimmunol.144.9.3347","article-title":"Quantitative analysis of cytokine gene expression in rheumatoid arthritis","volume":"144","author":"Firestein","year":"1990","journal-title":"J. Immunol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1385\/1-59259-805-6:295","article-title":"The mouse model of collagen-induced arthritis","volume":"102","author":"Brand","year":"2004","journal-title":"Methods Mol. Med."},{"key":"B12","first-page":"167","article-title":"Animal models of rheumatoid arthritis and their relevance to human disease","volume-title":"Pathophysiology","author":"Kannan","year":"2005"},{"key":"B13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s10067-012-2041-1","article-title":"Advances in research on animal models of rheumatoid arthritis","volume":"32","author":"Hu","year":"2013","journal-title":"Clin Rheumatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1093\/cid\/ciu185","article-title":"Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis","volume":"58","author":"Kourbeti","year":"2014","journal-title":"Clin Infect Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.autrev.2011.04.010","article-title":"Anti-TNF therapy: safety aspects of taking the risk","volume":"10","author":"Rosenblum","year":"2011","journal-title":"Autoimmun Rev."},{"key":"B16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2174\/157339711794474620","article-title":"Choice of biologic therapy for patients with rheumatoid arthritis: the infection perspective","volume":"7","author":"Keyser","year":"2011","journal-title":"Curr Rheumatol Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"2596","DOI":"10.3389\/fmicb.2017.02596","article-title":"Lactobacillus helveticus SBT2171 attenuates experimental autoimmune encephalomyelitis in mice","volume":"8","author":"Yamashita","year":"2018","journal-title":"Front Microbiol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11926-017-0696-y","article-title":"Can probiotic supplements improve outcomes in rheumatoid arthritis?","volume":"19","author":"Schorpion","year":"2017","journal-title":"Curr Rheumatol Rep."},{"key":"B19","first-page":"e82","article-title":"Dietary metabolites and the gut microbiota: an alternative approach to control inflammatory and autoimmune diseases","volume-title":"Clin Transl Immunol.","author":"Richards","year":"2016"},{"key":"B20","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3389\/fimmu.2017.00334","article-title":"Unraveling the differences between gram-positive and gram-negative probiotics in modulating protective immunity to enteric infections","volume":"8","author":"Kandasamy","year":"2017","journal-title":"Front Immunol."},{"key":"B21","first-page":"fnw212","article-title":"Escherichia coli strain Nissle 1917-from bench to bedside and back: history of a special Escherichia coli strain with probiotic properties","volume-title":"FEMS Microbiol Lett.","author":"Sonnenborn","year":"2016"},{"key":"B22","doi-asserted-by":"publisher","first-page":"8693","DOI":"10.1007\/s00253-016-7829-5","article-title":"Genetic engineering of probiotic Escherichia coli Nissle 1917 for clinical application","volume":"100","author":"Ou","year":"2016","journal-title":"Appl Microbiol Biotechnol."},{"key":"B23","first-page":"4376","article-title":"The delicate balance in genetically engineering live vaccines","volume-title":"Vaccine","author":"Galen","year":"2014"},{"key":"B24","first-page":"39","article-title":"Salmonella vaccines: conduits for protective antigens","volume-title":"J Immunol.","author":"Clark-Curtiss","year":"2018"},{"key":"B25","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1146\/annurev-food-030216-030207","article-title":"Milk glycans and their interaction with the infant-gut microbiota","volume":"9","author":"Kirmiz","year":"2018","journal-title":"Annu Rev Food Sci Technol."},{"key":"B26","first-page":"1179552217752679","article-title":"Saccharomyces boulardii CNCM I-745 improves intestinal enzyme function: a trophic effects review","volume-title":"Clin Med Insights Gastroenterol.","author":"Mor\u00e9","year":"2018"},{"key":"B27","first-page":"224","article-title":"Synthetic biology in probiotic lactic acid bacteria: at the frontier of living therapeutics","volume-title":"Curr Opin Biotechnol.","author":"Mays","year":"2018"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1093\/nar\/gkw1045","article-title":"Engineering robust and tunable spatial structures with synthetic gene circuits","volume":"45","author":"Kong","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"5929","DOI":"10.1128\/AEM.70.10.5929-5936.2004","article-title":"Improved stress tolerance of GroESL-overproducing Lactococcus lactis and probiotic Lactobacillus paracasei NFBC 338","volume":"70","author":"Desmond","year":"2004","journal-title":"Appl Environ Microbiol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/1348-0421.12397","article-title":"Oral immunization of mice with engineered Lactobacillus gasseri NM713 strain expressing Streptococcus pyogenes M6 antigen","volume":"60","author":"Mansour","year":"2016","journal-title":"Microbiol Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"6091","DOI":"10.1128\/AEM.01533-16","article-title":"Multivalent chromosomal expression of the Clostridium botulinum serotype A neurotoxin heavy-chain antigen and the Bacillus anthracis protective antigen in Lactobacillus acidophilus","volume":"82","author":"O'Flaherty","year":"2016","journal-title":"Appl Environ Microbiol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"576","DOI":"10.3892\/ol.2013.1743","article-title":"Intranasal immunization with recombinant Lactococci carrying human papillomavirus E7 protein and mouse interleukin-12 DNA induces E7-specific antitumor effects in C57BL\/6 mice","volume":"7","author":"Li","year":"2014","journal-title":"Oncol Lett."},{"key":"B33","doi-asserted-by":"publisher","first-page":"800","DOI":"10.3389\/fmicb.2017.00800","article-title":"Use of wild type or recombinant lactic acid bacteria as an alternative treatment for gastrointestinal inflammatory diseases: a focus on inflammatory bowel diseases and mucositis","volume":"8","author":"Carvalho","year":"2017","journal-title":"Front Microbiol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1128\/AEM.03296-13","article-title":"Genetically engineered immunomodulatory Streptococcus thermophilus strains producing antioxidant enzymes exhibit enhanced anti-inflammatory activities","volume":"80","author":"Del Carmen","year":"2014","journal-title":"Appl Environ Microbiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12934-016-0506-7","article-title":"Recombinant Lactococcus lactis NZ9000 secretes a bioactive kisspeptin that inhibits proliferation and migration of human colon carcinoma HT-29 cells","volume":"15","author":"Zhang","year":"2016","journal-title":"Microb Cell Fact."},{"key":"B36","first-page":"e0176286","article-title":"Genetically engineered probiotic for the treatment of phenylketonuria (PKU); assessment of a novel treatment in vitro and in the PAHenu2 mouse model of PKU","volume-title":"PLoS ONE","author":"Durrer","year":"2017"},{"key":"B37","doi-asserted-by":"publisher","first-page":"22","DOI":"10.3389\/fimmu.2017.00022","article-title":"Applications of genetically modified immunobiotics with high immunoregulatory capacity for treatment of inflammatory bowel diseases","volume":"8","author":"Shigemori","year":"2017","journal-title":"Front Immunol."},{"key":"B38","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s12934-015-0313-6","article-title":"Lactic acid bacteria: reviewing the potential of a promising delivery live vector for biomedical purposes","volume":"14","author":"Cano-Garrido","year":"2015","journal-title":"Microb Cell Fact."},{"key":"B39","unstructured":"Microbiome Therapeutics and Diagnostics Market 2017-2030"},{"key":"B40","first-page":"e0117825","article-title":"Milk-based nutraceutical for treating autoimmune arthritis via the stimulation of IL-10- and TGF-\u00df-producing CD39+ regulatory T cells","volume-title":"PLoS ONE","author":"Maddaloni","year":"2015"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1097\/MIB.0000000000001274","article-title":"Interleukin-27 is a potential rescue therapy for acute severe colitis through interleukin-10-dependent, T-cell-independent attenuation of colonic mucosal innate immune responses","volume":"23","author":"McLean","year":"2017","journal-title":"Inflamm Bowel Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.cgh.2006.03.028","article-title":"A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease","volume":"4","author":"Braat","year":"2006","journal-title":"Clin Gastroenterol Hepatol."},{"key":"B43","first-page":"785","article-title":"Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10","volume-title":"Nat Biotechnol.","author":"Steidler","year":"2003"},{"key":"B44","first-page":"16","article-title":"Interleukin-35 on B cell and T cell induction and regulation","volume-title":"J Inflamm (Lond).","author":"Huang","year":"2017"},{"key":"B45","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/ni.2227","article-title":"The composition and signaling of the IL-35 receptor are unconventional","volume":"13","author":"Collison","year":"2012","journal-title":"Nat Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nm.3554","article-title":"Interleukin-35 induces regulatory B cells that suppress autoimmune disease","volume":"20","author":"Wang","year":"2014","journal-title":"Nat Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1002\/eji.200737810","article-title":"IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells","volume":"37","author":"Niedbala","year":"2007","journal-title":"Eur J Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"7144","DOI":"10.4049\/jimmunol.0902739","article-title":"IL-35 stimulation of CD39+ regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10","volume":"184","author":"Kochetkova","year":"2010","journal-title":"J Immunol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1038\/ni.1952","article-title":"IL-35-mediated induction of a potent regulatory T cell population","volume":"11","author":"Collison","year":"2010","journal-title":"Nat Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.jneuroim.2012.10.005","article-title":"Epstein-Barr virus-induced gene 3 negatively regulates neuroinflammation and T cell activation following coronavirus-induced encephalomyelitis","volume":"254","author":"Tirotta","year":"2013","journal-title":"J Neuroimmunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"12633","DOI":"10.1038\/srep12633","article-title":"Interleukin-35 administration counteracts established murine type 1 diabetes\u2013possible involvement of regulatory T cells","volume":"5","author":"Singh","year":"2015","journal-title":"Sci Rep."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/jcmm.13428","article-title":"IL-35 recombinant protein reverses inflammatory bowel disease and psoriasis through regulation of inflammatory cytokines and immune cells","volume":"22","author":"Wang","year":"2018","journal-title":"J Cell Mol Med."},{"key":"B53","first-page":"2877","article-title":"CCR6 expression defines regulatory effector\/memory-like cells within the CD25+CD4+ T-cell subset","volume-title":"Blood","author":"Kleinewietfeld","year":"2005"},{"key":"B54","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1084\/jem.20091021","article-title":"CCR6 is expressed on an IL-10-producing, autoreactive memory T cell population with context-dependent regulatory function","volume":"207","author":"Rivino","year":"2010","journal-title":"J Exp Med."},{"key":"B55","first-page":"15043","article-title":"The abnormal expression of CCR4 and CCR6 on Tregs in rheumatoid arthritis","volume":"8","author":"Li","year":"2015","journal-title":"Int J Clin Exp Med."},{"key":"B56","first-page":"e47244","article-title":"L. plantarum, L. salivarius, and L. lactis attenuate Th2 responses and increase Treg frequencies in healthy mice in a strain dependent manner","volume-title":"PLoS ONE","author":"Smelt","year":"2012"},{"key":"B57","first-page":"517","article-title":"Induction of ovalbumin-specific tolerance by oral administration of Lactococcus lactis secreting ovalbumin","volume-title":"Gastroenterology","author":"Huibregtse","year":"2007"},{"key":"B58","first-page":"1225","article-title":"Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression","volume-title":"Blood","author":"Borsellino","year":"2007"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1053\/j.gastro.2018.06.078","article-title":"Expression of CCR6 and CXCR6 by gut-derived CD4+\/CD8\u03b1+ T-regulatory cells, which are decreased in blood samples from patients with inflammatory bowel diseases","volume":"155","author":"Godefroy","year":"2018","journal-title":"Gastroenterolog"},{"key":"B60","doi-asserted-by":"publisher","first-page":"4654","DOI":"10.4049\/jimmunol.1100530","article-title":"Segregated regulatory CD39+ CD4+ T cell function: TGF-\u03b2-producing Foxp3\u2212 and IL-10-producing Foxp3+ cells are interdependent for protection against collagen-induced arthritis","volume":"187","author":"Kochetkova","year":"2011","journal-title":"J Immunol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"804","DOI":"10.4049\/jimmunol.1302018","article-title":"Oral Escherichia coli colonization factor antigen I fimbriae ameliorate arthritis via IL-35, not IL-27","volume":"192","author":"Kochetkova","year":"2014","journal-title":"J Immunol."},{"key":"B62","first-page":"e25833","article-title":"Enhanced Th17-cell responses render CCR2-deficient mice more susceptible for autoimmune arthritis","volume-title":"PLoS ONE","author":"Rampersad","year":"2011"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1084\/jem.20062512","article-title":"Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression","volume":"204","author":"Deaglio","year":"2007","journal-title":"J Exp Med."},{"key":"B64","first-page":"153","article-title":"Human CD39+ Treg cells express Th17-associated surface markers and suppress IL-17 via a Stat3-dependent mechanism","volume-title":"J Interferon Cytokine Res.","author":"Magid-Bernstein","year":"2017"},{"key":"B65","first-page":"1291","article-title":"Stat3 programs Th17-specific regulatory T cells to control GN","volume-title":"J Am Soc Nephrol.","author":"Kluger","year":"2014"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02691\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T08:55:27Z","timestamp":1694076927000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2018.02691\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,20]]},"references-count":65,"alternative-id":["10.3389\/fimmu.2018.02691"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2018.02691","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,20]]},"article-number":"2691"}}